Pathogen- and Microbial- Associated Molecular Patterns (PAMPs/MAMPs) and the Innate Immune Response in Crohn’s Disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/B978-0-12-805417-8.00014-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-TNF-α therapies for the treatment of Crohn’s disease: the past, present and future

  2016cited by this paper
• Mucosa-attached bacterial community in Crohn's disease coheres with the clinical disease activity index.

  2016cited by this paper
• Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease

  2016cited by this paper
• Advances in the development of new biologics in inflammatory bowel disease

  2016cited by this paper
• Inflammatory bowel disease imaging: Current practice and future directions.

  2016cited by this paper
• Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.

  2016cited by this paper
• Nod2 Deficiency Leads to a Specific and Transmissible Mucosa-associated Microbial Dysbiosis Which Is Independent of the Mucosal Barrier Defect.

  2016cited by this paper
• Innate immune pattern recognition: a cell biological perspective.

  2015cited by this paper
• Dysbiosis of the gut microbiota in disease

  2015cited by this paper
• Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives.

  2015cited by this paper
• Peptidoglycan Modifications Tune the Stability and Function of the Innate Immune Receptor Nod2.

  2015cited by this paper
• The role and utility of faecal markers in inflammatory bowel disease

  2015cited by this paper
• Update on the Medical Management of Crohn’s Disease

  2015cited by this paper
• The Molecular Chaperone HSP70 Binds to and Stabilizes NOD2, an Important Protein Involved in Crohn Disease*

  2014cited by this paper
• Impaired Innate Immune Function Associated with Fecal Supernatant from Crohn's Disease Patients: Insights into Potential Pathogenic Role of the Microbiome

  2014cited by this paper
• Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis.

  2014cited by this paper
• Effectiveness of Anti-TNFα for Crohn Disease: Research in a Pediatric Learning Health System

  2014cited by this paper
• The microbiome in inflammatory bowel disease: current status and the future ahead.

  2014cited by this paper
• Mapping of Crohn's disease outcomes to faecal calprotectin levels in patients maintained on biologic therapy

  2014cited by this paper
• The treatment-naive microbiome in new-onset Crohn's disease.

  2014cited by this paper
• Host–microorganism interactions in lung diseases

  2014cited by this paper
• Commentary: predicting complicated Crohn's disease and surgery – phenotypes, genetics, serology and psychological characteristics of a population‐based cohort

  2013cited by this paper
• p62/SQSTM1 Enhances NOD2-Mediated Signaling and Cytokine Production through Stabilizing NOD2 Oligomerization

  2013cited by this paper
• Wall teichoic acids of gram-positive bacteria.

  2013cited by this paper
• Peptidoglycan hydrolases, bacterial shape, and pathogenesis.

  2013cited by this paper
• Highlights in IBD Epidemiology and Its Natural History in the Paediatric Age

  2013cited by this paper
• Terminal Restriction Fragment Length Polymorphism Analysis of the Gut Microbiota Profiles of Pediatric Patients with Inflammatory Bowel Disease

  2012cited by this paper
• Beyond growth: novel functions for bacterial cell wall hydrolases.

  2012cited by this paper
• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

  2012cited by this paper
• Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population

  2012cited by this paper
• The gut microbiota in IBD

  2012cited by this paper
• Structure, Function and Diversity of the Healthy Human Microbiome

  2012cited by this paper
• Proteasomal Degradation of Nod2 Protein Mediates Tolerance to Bacterial Cell Wall Components*

  2012cited by this paper
• Role of Calprotectin in Infection and Inflammation.

  2012cited by this paper
• Pathogen Sensing by Nucleotide-binding Oligomerization Domain-containing Protein 2 (NOD2) Is Mediated by Direct Binding to Muramyl Dipeptide and ATP

  2012cited by this paper
• The Innate Immune Protein Nod2 Binds Directly to MDP, a Bacterial Cell Wall Fragment

  2012cited by this paper
• Changes of the cytokine profile in inflammatory bowel diseases.

  2012cited by this paper
• Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment

  2012cited by this paper
• The ever-expanding function of NOD2: autophagy, viral recognition, and T cell activation.

  2011cited by this paper
• Therapeutic Rescue of Misfolded Mutants: Validation of Primary High Throughput Screens for Identification of Pharmacoperone Drugs

  2011cited by this paper
• Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives

  2011cited by this paper
• Altered gut microbiota composition in immune-impaired Nod2−/− mice

  2011cited by this paper
• Detection bias and the association between inflammatory bowel disease and Salmonella and Campylobacter infection

  2011cited by this paper
• Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.

  2011cited by this paper
• High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease

  2011cited by this paper
• Genetics and pathogenesis of inflammatory bowel disease

  2011cited by this paper
• What is new with Nods?

  2011cited by this paper
• Fecal HMGB1 Is a Novel Marker of Intestinal Mucosal Inflammation in Pediatric Inflammatory Bowel Disease

  2011cited by this paper
• Innate immunity in allergic disease

  2011cited by this paper
• Cutting Edge: Crohn’s Disease-Associated Nod2 Mutation Limits Production of Proinflammatory Cytokines To Protect the Host from Enterococcus faecalis-Induced Lethality

  2011cited by this paper
• The bacterial cell envelope.

  2010cited by this paper
• Proinflammatory cytokines underlying the inflammation of Crohn's disease

  2010cited by this paper
• Differences in gut microbial metabolism are responsible for reduced hippurate synthesis in Crohn's disease

  2010cited by this paper
• Expression and regulation of the chemokine CXCL16 in Crohn's disease and models of intestinal inflammation

  2010cited by this paper
• T cell intrinsic role of Nod2 in promoting type I immunity against Toxoplasma gondii

  2009cited by this paper
• Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide

  2009cited by this paper
• Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes

  2009cited by this paper
• Mycobacterium avium subspecies paratuberculosis in children with early‐onset Crohn's disease

  2009cited by this paper
• Metabolomics Reveals Metabolic Biomarkers of Crohn's Disease

  2009cited by this paper
• Cholesterol metabolism in active Crohn's disease

  2009cited by this paper
• Twin studies reveal specific imbalances in the mucosa‐associated microbiota of patients with ileal Crohn's disease

  2009cited by this paper
• Low counts of Faecalibacterium prausnitzii in colitis microbiota

  2009cited by this paper
• The gut microbiota shapes intestinal immune responses during health and disease

  2009cited by this paper
• Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

  2008cited by this paper
• Molecular analysis of the gut microbiota of identical twins with Crohn's disease

  2008cited by this paper
• Structural variation in the glycan strands of bacterial peptidoglycan.

  2008cited by this paper
• The microbial and danger signals that activate Nod-like receptors.

  2008cited by this paper
• Nod2-Dependent Th2 Polarization of Antigen-Specific Immunity1

  2008cited by this paper
• A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system

  2007cited by this paper
• Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.

  2007cited by this paper
• The Human Microbiome Project

  2007cited by this paper
• NOD2 Pathway Activation by MDP or Mycobacterium tuberculosis Infection Involves the Stable Polyubiquitination of Rip2*

  2007cited by this paper
• Deception point: Peptidoglycan modification as a means of immune evasion

  2007cited by this paper
• Rapid and noninvasive metabonomic characterization of inflammatory bowel disease.

  2007cited by this paper
• Unravelling the pathogenesis of inflammatory bowel disease

  2007cited by this paper
• Specificities of the fecal microbiota in inflammatory bowel disease

  2006cited by this paper
• Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

  2006cited by this paper
• Signalling pathways and molecular interactions of NOD1 and NOD2

  2006cited by this paper
• Differences between Tissue-Associated Intestinal Microfloras of Patients with Crohn's Disease and Ulcerative Colitis

  2006cited by this paper
• Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model disease

  2006cited by this paper
• Influence of Wall Teichoic Acid on Lysozyme Resistance in Staphylococcus aureus

  2006cited by this paper
• Location of tumour necrosis factor a by immunohistochemistry in chronic inflammatory bowel disease

  2006cited by this paper
• Modulation of neurodegeneration by molecular chaperones

  2005cited by this paper
• Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease.

  2005cited by this paper
• NOD-LRR proteins: role in host-microbial interactions and inflammatory disease.

  2005cited by this paper
• Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease

  2005cited by this paper
• Intestinal epithelial barrier and mucosal immunity

  2005cited by this paper
• Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach

  2005cited by this paper
• Nod2 Mutation in Crohn's Disease Potentiates NF-κB Activity and IL-1ß Processing

  2005cited by this paper
• Nod2-Dependent Regulation of Innate and Adaptive Immunity in the Intestinal Tract

  2005cited by this paper
• Identification of the namH Gene, Encoding the Hydroxylase Responsible for the N-Glycolylation of the Mycobacterial Peptidoglycan*

  2005cited by this paper
• Augmented expression of secondary lymphoid tissue chemokine and EBI1 ligand chemokine in Crohn’s disease

  2005cited by this paper
• Ultrastructure of the enlarged cecum in germfree rats

  2004cited by this paper
• Why are pathogenic staphylococci so lysozyme resistant? The peptidoglycan O‐acetyltransferase OatA is the major determinant for lysozyme resistance of Staphylococcus aureus

  2004cited by this paper
• Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease.

  2004cited by this paper
• Pharmacological chaperones: potential treatment for conformational diseases.

  2004cited by this paper
• Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer.

  2004cited by this paper
• High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease.

  2004cited by this paper
• The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO.

  2004cited by this paper
• Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease

  2004cited by this paper

• Antifungal Activity Enhancement of Cell-Free Streptomyces griseus Extract Obtained by Fermentation with Magnetic Manganese Ferrite Nanoparticles

  2024cites this paper
• Evaluating microbial protein elicitors for managing Cabbage Aphids in Brassica oleracea

  2024cites this paper
• Postbiotics: From emerging concept to application

  2022cites this paper
• A hemagglutinin from Pongamia pinnata (L.) Pierre seed

  2022cites this paper
• The Role of Endophytes in Combating Fungal- and Bacterial-Induced Stress in Plants

  2022cites this paper
• Circadian rhythms and the gut microbiome synchronize the host's metabolic response to diet.

  2021cites this paper
• Signaling Pathways and Downstream Effectors of Host Innate Immunity in Plants

  2021cites this paper
• Gut Microbiota Disorder, Gut Epithelial and Blood–Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways

  2019cites this paper